Jubilant Pharmova Ltd announced on Friday, August 16, that its subsidiary, Jubilant Biosys Ltd, through Jubilant Biosys Innovative Research Services Pte Ltd (JBIRSPL), will acquire an 80% stake in Pierre Fabre Laboratories’ Research & Development Centre in Saint Julien, France.
The deal, valued at approximately €4.4 million over two years, will be carried out through a newly established company in France, which will assume control of the R&D site and its operations. This acquisition is part of Jubilant Biosys’ strategy to expand its capabilities in biologics and antibody-drug conjugates (ADC).
The transaction is subject to the consultation of Pierre Fabre’s works council and the approval of the offer by Pierre Fabre, along with the finalization of definitive agreements and customary closing conditions. Once completed, the new company will manage the R&D Centre, with plans to partner with leading pharmaceutical and biotech firms in Europe and the United States.
This move is expected to enhance Jubilant Biosys’ drug discovery portfolio, focusing on biologics and ADCs, which are critical growth areas for the company. Under the agreement, Pierre Fabre may retain a 20% stake in the new company, investing around €1.1 million over two years.
This minority stake will be held for up to five years, during which Pierre Fabre may assist in transitioning the R&D Centre into a fully independent contract research organization (CRO). Pierre Fabre will not have access to any proprietary information or intellectual property related to the R&D Centre during this period. Additionally, Pierre Fabre has agreed to procure services from Jubilant Biosys worth €7 million over the first four years of the partnership.
